Day: November 12, 2020

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.“Receiving orphan drug designation for mitapivat in sickle cell disease is an important recognition of the tremendous unmet need among this patient community, which has historically been underserved,” said Chris Bowden, M.D., chief medical officer at Agios. “As the pioneers in PKR activation, we believe...

SAN RAMON, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) announced today that its Board of Directors elected Teresa S. Madden to the Board as an independent director, effective December 1, 2020.“We are delighted to have Teresa join our Board of Directors,” said Al White, President and CEO. “Teresa brings a unique perspective that combines operational excellence and financial acumen, with long-term experience in an industry that was continually being pushed to evolve and change. We look forward to Teresa’s advice and support as Cooper continues growing its business.”Ms. Madden is an independent director of Enbridge, Inc. (NYSE: ENB) where she serves on the governance committee and as chair of the audit, finance and risk committee. She previously served as a director of Peabody Energy Corporation (NYSE: BTU)...

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — 5:01 Acquisition Corp. (the “Company”) (NASDAQ: FVAM) announced today that the underwriter of its previously announced initial public offering of Class A common stock, par value $0.0001 per share, partially exercised its over-allotment option resulting in the issuance of an additional 256,273 shares at a price to the public of $10.00 per share for gross proceeds of approximately $2.6 million.The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.The Company’s shares of Class A common stock began trading on The Nasdaq Capital Market under the ticker symbol “FVAM” on October 14, 2020.BofA Securities acted as sole book-running manager...

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.“Vaxcyte continues to make steady progress in executing on our business objectives,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We advanced several important manufacturing activities for VAX-24, our 24-valent investigational pneumococcal conjugate vaccine, or PCV, designed to prevent invasive pneumococcal disease, as we proceed toward our anticipated IND filing in the second half of next year....

Columbus, OH, Nov. 12, 2020 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020, at 3:10 p.m. Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors.  A replay of the webcast will be available for seven days.Mary T. Finnegan Investor Relations +1-614-438-4748

HOUSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Crown Castle International Corp. (NYSE: CCI) (“Crown Castle”) announced today that Jay Brown, Crown Castle’s President and Chief Executive Officer, will present at one investor conference in November and Dan Schlanger, Crown Castle’s Executive Vice President and Chief Financial Officer, will present at two investor conferences in November. The presentations will be broadcast over the Internet, and the live audio webcast links will be available on Crown Castle’s website at www.crowncastle.com, where they will also be archived for replay.Mr. Schlanger is scheduled to present on Tuesday, November 17, 2020 at 10:20 a.m. Eastern Time at the New Street 2020 Conference: 5G. Infrastructure. Applications. Innovation. Disruption. The presentation is expected to last approximately 30 minutes.Mr....

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer (SITC) virtual annual meeting. HPN601 is the first conditionally active T cell engager program from Harpoon. It targets the tumor antigen epithelial cell adhesion molecule (EpCAM) and is based on Harpoon’s proprietary ProTriTAC™ T cell engager prodrug platform designed to remain inert systemically until its activation in the tumor by tumor-associated proteases and to enable the safe targeting of broadly expressed tumor antigens.The oral presentation today highlighted the following data:The successful use of a humanized rodent tumor...

Holmdel, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) — Monmouth Real Estate Investment Corporation (NYSE:MNR) today announced that Michael P. Landy, President and Chief Executive Officer, Kevin Miller, Chief Financial Officer, and Becky Coleridge, Vice President of Investor Relations, are scheduled to participate in Nareit’s REITworld: 2020 Virtual Annual Conference.Monmouth is scheduled to present on Tuesday, November 17, 2020, at 9:30 a.m. Eastern Time.In order to view the presentation live or on-demand, you must register on the REITworld website.Monmouth Real Estate Investment Corporation, founded in 1968, is one of the oldest public equity REITs in the world. The Company specializes in single tenant, net-leased industrial properties, subject to long-term leases, primarily to investment-grade tenants. Monmouth Real Estate is a fully integrated...

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today financial and operating results for the quarter ended September 30, 2020.RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTSJohn A. Roberts, Chief Executive Officer of Cancer Genetics stated, “During Q3 2020, we continued to make advances to enhance value for our shareholders and customers. The key event of the quarter was signing a definitive agreement to merge with StemoniX. Based on our lengthy search for a merger partner since last year, StemoniX proved to be the most attractive opportunity for our shareholders by extracting meaningful value from synergies with our vivoPharm drug discovery business and the continued transformation of...

Charlotte, NC, Nov. 12, 2020 (GLOBE NEWSWIRE) — Ballantyne Strong, Inc. (NYSE American: BTN) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2020.Financial and Operational Highlights          ●     Convergent profitability improved with continued growth in recurring revenue                        ○     Year-over-year segment gross margins increased to 47.9% from 32.4%, segment operating income improved by 169% and segment Adjusted EBITDA grew 88% to $1.7 million          ●     Strong Entertainment began to see meaningful signs of recovery as cinema exhibitors and other entertainment operators began reopening worldwide                        ○     Revenue decreased year over year due to COVID-19 impact on cinema operators                                                        ...